Federated Hermes, INC
Market Movers (8-K)
NYSE
Federated Hermes announced record assets under management of $911.6 billion and Q2 2026 diluted EPS of $1.38, up from $1.16 year-over-year.
NYSE
Federated Hermes reported record assets under management of $907.1 billion and an 11.8% dividend increase for Q1 2026.
NYSE
Federated Hermes, Inc. has finalized its acquisition of an 80% stake in FCP Fund Manager, L.P., a U.S. real estate investment manager, for up to $331 million.
NYSE
Federated Hermes' subsidiary, Hermes GPE LLP, is facing a lawsuit in the UK High Court alleging professional negligence and breach of contract related to a 2019 investment in Swedish wind farms.
Worse than expected
NYSE
Federated Hermes, Inc. announced record assets under management of $902.6 billion and significant earnings growth for both the fourth quarter and full-year 2025.
Better than expected
NYSE
Federated Hermes, Inc. announced significant executive leadership appointments in its global investment and distribution divisions, effective April 30, 2026, as part of a planned succession.
Quarterly Earnings (10-Q)
NYSE
Federated Hermes reports increased revenue and net income for Q2 2026, driven by the FCP acquisition and market appreciation in equity assets.
NYSE
Federated Hermes reports increased revenue and assets under management in Q1 2026, but net income declined due to higher operating expenses and lower performance fees, with EPS boosted by share repurchases.
Worse than expected
NYSE
Federated Hermes posts significant Q3 and YTD financial gains, driven by AUM growth and strategic acquisitions, amidst a shifting regulatory landscape.
Delay expected
Better than expected
Capital raise
NYSE
Federated Hermes, Inc. announced robust financial results for the second quarter and first half of 2025, driven by significant increases in net income and earnings per share, alongside growth in managed assets and a strategic acquisition in the UK renewable energy sector.
Better than expected
Delay expected
NYSE
10-Q: Federated Hermes Reports Q1 2025 Results: Revenue and Earnings Increase Amid Regulatory Shifts
Federated Hermes' Q1 2025 results show increased revenue and net income, driven by growth in money market assets and strategic business developments, despite ongoing regulatory complexities.
Better than expected
Delay expected
NYSE
Federated Hermes' Q3 2024 results show a mixed performance with increased revenue offset by an intangible asset impairment and changes in asset mix.
Worse than expected
Annual Reports (10-K)
NYSE
Federated Hermes, Inc. announced robust financial results for 2025, driven by significant AUM growth and strategic acquisitions, despite a dynamic regulatory landscape.
Better than expected
Delay expected
NYSE
Federated Hermes' 2024 10-K filing reveals a 9% increase in AUM to $829.6 billion amid evolving regulatory landscape and strategic shifts.
Worse than expected
Delay expected
NYSE
Federated Hermes files its annual 10-K report, highlighting a code of ethics update, $757.6 billion in assets under management, and a detailed overview of its business and regulatory environment.
Insider Trading (Form 4)
NYSE
Federated Hermes, Inc. executive Saker Anwar Nusseibeh reported a sale of 8,950 shares of Class B Common Stock.
NYSE
Federated Hermes, Inc. Vice President Paul A. Uhlman reported a sale of 1,021 shares of Class B Common Stock on May 26, 2026, to cover tax obligations from vested restricted stock.
NYSE
Peter J. Germain of Federated Hermes, Inc. reported a transaction involving the sale of Class B Common Stock.
NYSE
Thomas R. Donahue, VP, CFO & Treasurer of Federated Hermes, Inc., reported transactions involving Class B Common Stock.
NYSE
Peter J. Germain, EVP and CLO of Federated Hermes, Inc., sold 5,000 shares of Class B Common Stock on May 15, 2026.
NYSE
Vice President Bryan M. Burke sold 4,000 shares of Federated Hermes, Inc. Class B Common Stock on May 7, 2026.
Proxy Statements (Def-14A)
NYSE
Federated Hermes has filed an information statement regarding the upcoming Annual Meeting of Shareholders scheduled for April 24, 2025, covering the election of directors and other business matters.
NYSE
Federated Hermes files a Schedule 14C information statement detailing director nominees, executive compensation, related person transactions, and corporate governance policies in preparation for its annual shareholder meeting.
Institutional Holdings (13F)
NYSE
Federated Hermes, Inc. has submitted its Form 13F filing for the quarter ended March 31, 2026, detailing its institutional investment holdings.
NYSE
Federated Hermes, Inc. has filed its Form 13F-HR, revealing significant equity holdings totaling over $59.85 billion across 3,963 positions as of December 31, 2025.
NYSE
Federated Hermes, Inc. filed its Form 13F-HR, revealing $56.6 billion in managed equity assets across 4,188 positions as of September 30, 2025.
NYSE
Federated Hermes, Inc. filed its Q2 2025 13F report, revealing $53.11 billion in managed equity assets across 4,129 positions.
NYSE
Federated Hermes, Inc. reports its Form 13F holdings for the quarter ended March 31, 2025, revealing significant positions in a wide array of securities.
NYSE
Federated Hermes, Inc. files its Form 13F for the quarter ended December 31, 2024, reporting $45.66 billion in managed assets across 4,013 holdings.
Schedule 13D - Activist Investments
NYSE
Federated Hermes, Inc. and affiliated entities have increased their beneficial ownership in Minerva Neurosciences, Inc. to 19.32% and acquired additional convertible preferred stock and warrants in a private placement.
Capital raise
Schedule 13G - Passive Investments
NYSE
SCHEDULE: SCYNEXIS Inc. Ownership Update
Federated Hermes, Inc. and related entities report a 4.03% beneficial ownership stake in SCYNEXIS Inc. as of June 30, 2026.
NYSE
SCHEDULE: SCYNEXIS Inc. Ownership Update
Federated Hermes, Inc. and associated entities report a 4.45% beneficial ownership stake in SCYNEXIS Inc. common stock as of June 30, 2026.
NYSE
Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 4.15% of Ovid Therapeutics Inc. common stock as of June 30, 2026.
NYSE
Federated Hermes, Inc. and associated entities have filed a Schedule 13G, reporting beneficial ownership of 17.17% of Minerva Neurosciences, Inc. common stock as of June 30, 2026.
NYSE
Federated Hermes, Inc. and associated entities report a beneficial ownership stake of 4.59% in MGP Ingredients, Inc. as of June 30, 2026.
NYSE
SCHEDULE: Federated Hermes Discloses LifeMD Stake
Federated Hermes, Inc. and related entities have reported beneficial ownership of 5.68% of LifeMD, Inc. common stock as of June 30, 2026.